Additional criteria on scintigraphic testing for diagnosis of rapid colonic transit in patients with chronic diarrhea.
IBS
bile acid diarrhea
functional diarrhea
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
revised:
03
09
2024
received:
01
05
2024
accepted:
06
09
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Colonic transit (CT) measured by validated scintigraphy using We evaluated two adult patient cohorts: 701 clinical patients (1994-2023) with chronic diarrhea and 76 research participants with irritable bowel syndrome with diarrhea (N = 63) or bile acid diarrhea (BAD, N = 13). Results of ∆GC were compared to 220 healthy controls' 95th percentiles (%ile) (≥2.0 females and ≥2.2 males). In the research cohort, we also analyzed (Spearman correlation) colonic ∆GC with ascending colon emptying T Among 701 clinical patients with normal GC24, 160 (22.3%) had rapid CT based on ∆GC 95th %ile in health. Among 76 research participants, an additional 20.6% IBS-D and 23% BAD had rapid CT ∆GC. Younger age and absence of diabetes mellitus were predictive of rapid ∆GC. ∆GC significantly correlated with AC T ∆GC identified an additional 21%-23% patients with rapid colonic transit among patients with diarrhea and normal GC24.
Sections du résumé
BACKGROUND
BACKGROUND
Colonic transit (CT) measured by validated scintigraphy using
METHODS
METHODS
We evaluated two adult patient cohorts: 701 clinical patients (1994-2023) with chronic diarrhea and 76 research participants with irritable bowel syndrome with diarrhea (N = 63) or bile acid diarrhea (BAD, N = 13). Results of ∆GC were compared to 220 healthy controls' 95th percentiles (%ile) (≥2.0 females and ≥2.2 males). In the research cohort, we also analyzed (Spearman correlation) colonic ∆GC with ascending colon emptying T
KEY RESULTS
RESULTS
Among 701 clinical patients with normal GC24, 160 (22.3%) had rapid CT based on ∆GC 95th %ile in health. Among 76 research participants, an additional 20.6% IBS-D and 23% BAD had rapid CT ∆GC. Younger age and absence of diabetes mellitus were predictive of rapid ∆GC. ∆GC significantly correlated with AC T
CONCLUSIONS & INFERENCES
CONCLUSIONS
∆GC identified an additional 21%-23% patients with rapid colonic transit among patients with diarrhea and normal GC24.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14917Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and motility societies. Neurogastroenterol Motil. 2011;23(1):8‐23.
Szarka LA, Camilleri M. Methods for the assessment of small‐bowel and colonic transit. Semin Nucl Med. 2012;42(2):113‐123.
Kolar GJ, Camilleri M, Burton D, Nadeau A, Zinsmeister AR. Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice. Neurogastroenterol Motil. 2014;26(1):131‐138.
Khoshbin K, Busciglio I, Burton D, Breen‐Lyles MK, Camilleri M. Expanding criteria for slow colonic transit in patients being evaluated for chronic constipation by scintigraphy. Neurogastroenterol Motil. 2020;32(9):e13878.
Maurer AH, Camilleri M, Donohoe K, et al. The SNMMI and EANM practice guideline for small‐bowel and colon transit 1.0. J Nucl Med. 2013;54(11):2004‐2013.
Camilleri M, Carlson P, BouSaba J, et al. Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. Gut. 2023;72(1):54‐65.
von der Ohe MR, Camilleri M, Kvols LK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993;329(15):1073‐1078.
Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med. 1997;38(11):1807‐1810.
Proano M, Camilleri M, Phillips SF, Thomforde GM, Brown ML, Tucker RL. Unprepared human colon does not discriminate between solids and liquids. Am J Physiol. 1991;260(1 Pt 1):G13‐G16.
Ziessman HA, Jeyasingam M, Khan AU, McMahan Z, Pasricha PJ. Experience with esophagogastrointestinal transit scintigraphy in the initial 229 patients: multiple regions of dysmotility are common. J Nucl Med. 2021;62(1):115‐122.
Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology. 1987;92(1):40‐47.
Hinton JM, Lennard‐Jones JE, Young AC. A ne method for studying gut transit times using radioopaque markers. Gut. 1969;10(10):842‐847.
Sadik R, Stotzer PO, Simren M, et al. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil. 2008;20(3):197‐205.
Sadik R, Björnsson E, Simrén M. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2010;22(1):102‐108.
Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol. 2012;107(5):754‐760.
Deiteren A, Camilleri M, Bharucha AE, et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil. 2010;22(4):415‐423.e95.
Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(10):1270‐1275.e1.
Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17(5):643‐650.
Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365‐1375.
Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;6(7):772‐781.
Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022;163(1):137‐151.
Smalley W, Falck‐Ytter C, Carrasco‐Labra A, Wani S, Lytvyn L, Falck‐Ytter Y. AGA clinical practice guidelines on the laboratory evaluation of functional diarrhea and diarrhea‐predominant irritable bowel syndrome in adults (IBS‐D). Gastroenterology. 2019;157(3):851‐854.
Maurer AH, Krevsky B, Knight LC, et al. Opioid and opioid‐like drug effects on whole‐gut transit measured by scintigraphy. J Nucl Med. 1996;37(5):818‐822.
Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender‐related differences in slowing colonic transit by a 5‐HT3 antagonist in subjects with diarrhea‐predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96(9):2671‐2676.
Thumshirn M, Coulie B, Camilleri M, et al. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14(7):869‐878.
Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5‐HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2000;14(6):775‐782.
Saslow SB, Scolapio JS, Camilleri M, et al. Medium‐term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Gut. 1998;42(5):628‐634.
Ford AC, Wright‐Hughes A, Alderson SL, et al. Amitriptyline at low‐dose and titrated for irritable bowel syndrome as second‐line treatment in primary care (ATLANTIS): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2023;402(10414):1773‐1785.
Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:159‐166.
Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005;54:601‐607.
BouSaba J, Zheng T, Dilmaghani S, Johnson S, Chen J, Camilleri M. Effect of rapid colonic transit on stool microbiome and short‐chain fatty acids in diarrhoea‐predominant irritable bowel syndrome. Gut. 2024;73(2):375‐376.
Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol. 2002;282(3):G443‐G449.
Delgado‐Aros S, Camilleri M, Garcia MA, Burton D, Busciglio I. High body mass alters colonic sensory‐motor function and transit in humans. Am J Physiol Gastrointest Liver Physiol. 2008;295(2):G382‐G388.
Delgado‐Aros S, Locke GR 3rd, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population‐based study. Am J Gastroenterol. 2004;99(9):1801‐1806.